CMS Entry id: 2709 | Channel: Blog landing page | Template: blog/index

Login
Facebook YouTube Twitter Linkedin
Facebook YouTube Twitter Linkedin

Blog

18 September 2018

How can you measure behavior more accurately in your clinical trials?

Drug development typically relies upon clinical endpoints established within very controlled laboratory environments. Digital health technologies now provide the opportunity to transition data collection from the clinic into people’s personal lives, thereby providing more accurate conclusions about how a compound can influence their day-to-day life. 

18 September 2018

How can digital health improve the signal-to-noise ratio in your clinical trials?

The contemporary framework for designing clinical trials is to build a comprehensive cognitive profile of the patient population from thorough but infrequent assessments. However, this framework struggles to capture the daily fluctuations in mood and cognition that many individuals with psychiatric disorders experience. Here we will discuss how the advent of digital health offers the opportunity to capture a more holistic representation of patients’ cognitive function from high-frequency assessments.

18 September 2018

Four reasons to use digital health in your clinical trials

In the first of our digital health series we will outline what the term means, and the opportunities offered, within the context of clinical trials in psychiatry. 

5 September 2018

CANTAB for cognitive screening in a young adult mental health unit

Mental health researcher at the University of Sydney: Brain and Mind Centre, Ashleigh Tickell, recently submitted her PhD on the feasibility of cognitive screening as standard clinical care in a young adult mental health unit. We caught up with Ashleigh to find out the outcomes of using CANTAB for her project.

29 August 2018

Using CANTAB to investigate age-related cognitive changes associated with Alzheimer's disease in Down syndrome

PhD researcher, Rosalyn Hithersay, spoke to us about her recent publication on which cognitive tests are most sensitive to the early stages of dementia in Down syndrome.

14 August 2018

What is the optimal approach for using digital cognitive biomarkers in clinical trials?

Digital cognitive biomarkers are typically active or passive: but which approach enhances clinical trial success? Here we will define how active and passive cognitive biomarkers function in clinical trials, to conclude their optimal application.

web-based testing, wearables, voice recognition, virtual clinical trials, transdiagnostic, test-retest, technology, swm, subjective measures, stigma, spatial planning, social cognition, smartphones, set-shifting, schizophrenia research, schizophrenia, rvp, rule learning, research funding, remote testing, regulations, recruitment, real-world assessments, prodromal, pro-cognitive, presenteeism, precision psychiatry, pre-clinical, pharmacovigilance, personalised medicine, patient-centric, patient screening, patient recruitment, parkinson's disease, pal, ots, opinion piece, occupational health, objective measures, novel, normative data, neurotech, neuroscience, near-patient testing, multiple sclerosis, ms, modelling, mental wellbeing, mental health, mci, major depression, machine learning, lifespan, inpatients, ied, high frequency, healthcare, ert, episodic memory, epidemiology, emotion recognition, efficacy, ecological momentary assessments, ebt, ebbinghaus, early alzheimer's disease, drug development, dopamine, digital tools, digital health, depression, dementia, cognitive testing, cognitive science, cognitive safety, cognitive impairment, cognitive function, cognitive dysfunction, cognitive deficits, cognitive biomarkers, cognitive assessment, cognition kit, cognition, cns summit, clinical trials, clinical trial, clinical symptoms, cias, cgt, cantab research grant, cantab for clinical trials, cantab, brain health, biomarkers, awards, automatic speech recognition, attention, alzheimer's disease, affective cognition, absenteeism,